Levosert (20mcg/24 hours) Intrauterine Delivery System (Levonorgesterel 52mg) is indicated for contraception and treatment of heavy menstrual bleeding. Licensed for 3 year use since its launch in the UK in early 2015, Levosert has now been approved in the UK for 5 years use.
This document was updated in March 2019.
The FSRH CEU has produced a new product review for Kyleena which summarises the key differences in the product and clinical characteristics between Kyleena and other LNG-IUS available in the UK.
Manufactured by OCON Medical Ltd, the Intrauterine Ball (IUB™) SCu300B MIDI is a copper intrauterine device (Cu-IUD) comprised of copper beads with a total exposed copper surface of 300mm² strung on a flexible Nitinol (nickel/titanium alloy), PET-coated frame. Once the IUB is released from the 3.2mm diameter insertion tube into the uterus it coils into a spherical shape measuring 15mm in diameter. Download the product review in full here.
How effective is 20mcgEE/3mgDRSP as contraception?
20mcgEE/3mg DRSP is of comparable effectiveness to other combined oral contraceptives. [1,2,3] A large US observational study reports lower failure rates amongst users of a 24/4 EE/DRSP regimen than a 21/7 EE/DRSP regimen. The study also suggests greater contraceptive effectiveness of a 24/4 EE/DRSP regimen than with a 24/4 regimen containing EE in combination with norethisterone.
Diaphragms are non-hormonal barrier methods of contraception that protect women against pregnancy by preventing sperm reaching the cervix. A single size contraceptive cap, FemCap, has been available since 2004, but until recently diaphragm products have been made in a range of sizes and designs. As a result
women may have been required to try several types of diaphragm during the fitting process.
Jaydess® is a levonorgestrel intrauterine system (LNG-IUS) newly launched in the UK for contraception. It is a smaller, lower dose version of the Mirena® LNG-IUS.
Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).
The combined oral contraceptive Zoely® (Merck, Sharp, and Dohme Limited) has been licensed in Europe since 2011 and will be available in the UK from May 2013. Zoely will be the second UK combined oral contraceptive (COC) to contain estradiol and to be formulated as an extended regimen since the introduction of Qlaira® (Bayer plc.)